$

To the moon

[Westwater Resources Inc @WWR_Inc]

Permitting progress at Coosa.

$WWR has submitted a Section 404 permit application to the U.S. Army Corps of Engineers.

Another step in advancing a future domestic source of natural flake graphite - a critical mineral used in battery-grade graphite production.

#CriticalMinerals #Graphite #WWR

🔗https://t.co/YvJYxuC71d

#Graphite #CriticalMinerals #WWR

[Westwater Resources Inc @WWR_Inc]

The G7’s latest declaration on critical minerals reinforces the need to build secure, diversified supply chains, including domestic processing capacity.

$WWR is advancing both a potential U.S. graphite resource at Coosa and battery-grade graphite production at Kellyton.

LINK: https://t.co/vxyKXrek57

#G7 #CriticalMinerals #Graphite #WWR

[Humacyte @humacyte]

On National Nurses Day, we’re honoring the nurses who help vascular surgery teams restore blood flow, protect limbs, and guide patients through complex procedures and recovery.

From pre‑op assessment and patient preparation to vascular suite readiness, post‑op monitoring, and follow‑up care, you bring technical excellence and steady guidance. You help make the right treatment options available for procedures and watch closely for the changes that matter most after surgery. Just as importantly, you educate patients and families on the care and recovery plans, and you advocate so concerns are heard quickly and care stays coordinated.

At Humacyte, we’re proud to support vascular surgery innovation designed to work alongside your clinical judgment across every step of care. Thank you for your precision in the OR suite, your vigilance in recovery, and the trust you build with every patient.

Learn more about our innovations at https://t.co/9vMVYqyUN8

#NationalNursesDay #VascularSurgery #VascularCare #LimbSalvage #PatientEducation #NurseAdvocates #HealthcareInnovation #Humacyte

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc. All Rights Reserved.

[Westwater Resources Inc @WWR_Inc]

🚨 Upcoming Event 🚨

Westwater will participate in the D. Boral Capital Global Conference this week.

Executive Chairman Terence Cryan will be attending and sharing Westwater’s domestic mine-to-market graphite story.

#WWR #CriticalMinerals #Graphite

[Surf Air @SurfAir]

Surf Air Mobility Announces Details of SurfOS Commercial Launch Plan $SRFM

Read more: https://t.co/jV2le7kFyz

[Surf Air @SurfAir]

Two years of internal deployment created a proven product-market fit before external commercialization of SurfOS. In the last year, our Surf On Demand private charter team saw 32% more bookings for top brokers, 57% faster quote-to-close, and 40% more payments processed on-platform.

We are commercializing SurfOS core products and building agentic workflows and automated processes faster than ever before.

[Aurora @aurora_inno]

Next up: a new fleet of driverless trucks, based on the International® LT® Series vehicle, with nobody behind the wheel.

Equipped with our 2nd-gen commercial hardware kit designed to last a million miles at 50%+ lower cost, this fleet sets us up to exit 2026 with 200+ driverless trucks operating across the Sun Belt.

$AUR

[Aurora @aurora_inno]

Aurora and Volvo Autonomous Solutions have expanded their autonomous freight network.

The Aurora Driver-powered Volvo VNL Autonomous is hauling freight for a V.A.S customer on a new 200-mile route between Dallas and Oklahoma City, serving a customer endpoint which represents hundreds of miles daily.

$AUR Full announcement: https://t.co/QIsciCVMOW

[Humacyte @humacyte]

During Limb Loss and Limb Difference Awareness Month, we recognize the critical role of preparedness in vascular injury care.

Vascular injuries threaten both life and limb. Delayed intervention significantly increases the risk of tissue damage, fasciotomy, and amputation. Early intervention is crucial for limb salvage.1

Published data shows that amputation rates in patients with lower extremity arterial injuries increase as repair time extends beyond the first hour after injury. 1 Amputation rates increase from 6% to 11.7% after 1-3 hours, and 13.4% after 3-6 hours post injury. 1

Symvess® acellular tissue engineered vessel-tyod is the first and only FDA Approved, human-derived, bioengineered vessel for vascular injury repair. 2,3 Symvess is designed to be off-the-shelf, ready to use, with minimal preparation time. 2,3

Learn more about Symvess at https://t.co/7mVFSHK4nF

PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING,
AND FULL PRESCRIBING INFORMATION at https://t.co/Eg2XmrWjCQ

INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

BOXED WARNING: GRAFT FAILURE- Loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.

WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

REFERENCES: 1. Alarhayem A, et al. Impact of time to repair in outcomes in patients with lower extremity arterial injuries. J Vasc Surg. 2019; 69: 1519-1523. 2. Symvess U.S. Prescribing Information. Durham, NC. Humacyte Global, Inc. 3. Dahl S, et al. Readily available tissue-engineered vascular grafts. Sci Transl Med. 2011 Feb 2;3(68):68ra9.

#LimbLossAwareness #VascularInjury #MedicalInnovation #ReadyWhenItMatters #AmputeeCommunity #AmputeeCoalition # Symvess #Humacyte

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc. All Rights Reserved. US-SYM-000337

[Humacyte @humacyte]

Humacyte’s Marketing Authorization Application (MAA) has been accepted by the Israel Ministry of Health for use of Symvess® acellular, tissue‑engineered vessel-tyod for urgent arterial injury repair!(1)

The Ministry of Health has set a 180-working-day review period for the MAA. We are one step closer in our planned expansion of Symvess into multiple countries outside of the U.S.!

For more details read the full press release here: 🔗 https://t.co/f73UqsCuXu

PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at https://t.co/Eg2XmrWjCQ

INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.

WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

#Humacyte #Symvess #RegenerativeMedicine #VascularTrauma #MedicalInnovation #ATEV #Innovation
Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc. All Rights Reserved.

[Palantir @PalantirTech]

Congratulations to Airbus and Skywise on this milestone in the aviation ecosystem.

Palantir is proud of its longstanding partnership with Airbus that began on the collaboration during the A350 production ramp up.

Cristina Aguilar, SVP Customer Services, Commercial Aircraft at Airbus: "Our customers require resilient, end-to-end and interoperable digital solutions. The newly created Skywise will be the only provider to do so by combining OEM expertise and digital know-how."

[Westwater Resources Inc @WWR_Inc]

We're LIVE today at 2PM ET with @MaximGrp!

Register here: https://t.co/2FUi7qAoem

Maxim's Tate Sullivan will host a 1x1 fireside chat with $WWR Executive Chairman Terence Cryan.

#InvestorRelations #Graphite #WWR #CriticalMinerals

[Surf Air @SurfAir]

Surf Air Mobility Completes Implementation of Safety Management System for Part 135 Airline Operations $SRFM

Read more: https://t.co/bEQl5EGmB9

[Humacyte @humacyte]

We’re looking forward to connecting with the vascular community this spring. Join Humacyte at upcoming regional and national meetings to explore Symvess®, acellular tissue engineered vessel-tyod (ATEV™) and learn how our ready-off-the-shelf, human-derived vessel is supporting clinicians treating extremity vascular injuries.

Meet our team and experience Symvess firsthand—see it, feel it, suture it.

Where to meet us:
🔹 SCVS Annual Symposium — Mar 28–Apr 1 Chula Vista, San Diego
🔹 PHVS Symposium — Apr 17–18 Philadelphia, PA
🔹 SCVSS Annual Meeting — May 1–3 San Jose del Cabo, Mexico
🔹 Women’s Vascular Summit — May 1–2 Atlanta, GA

If you would like more program information, please reach out to [email protected]

Learn About Symvess here: https://t.co/1f77QQzkzn

PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING,

AND FULL PRESCRIBING INFORMATION at https://t.co/Eg2XmrWjCQ

INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.
GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.
WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

Trademarks are property of Humacyte Global, Inc

© 2026 Humacyte Global Inc. All Rights Reserved. US-SYM-000334

#Humacyte #Symvess #VascularSurgery #MedicalConferences #MedicalInnovation #Symposium #Biotech #WVS #SCVS #PHVS #SCVSS

[Westwater Resources Inc @WWR_Inc]

We're head to @MoneyShow in Miami this week (April 9–11). ☀️

Looking forward to connecting with investors and sharing our domestic, mine-to-market graphite story.

🔗https://t.co/BDH1Hwo2Tv

#CriticalMinerals #WWR #Moneyshow #Graphite

[Humacyte @humacyte]

On World Health Day, Humacyte celebrates the power of innovation to improve lives.

Our mission has always been rooted in a deep connection to improving patient outcomes — the belief that science, compassion, and collaboration can create a healthier future for every patient. From advancing bioengineered tissues to supporting clinicians on the front lines of care, we are driven by the people whose lives and stories inspire our work every day.

Today and every day, we reaffirm our commitment to building solutions that put patients first and expand what’s possible in regenerative medicine.
Humacyte cares deeply about every patient, and we’re proud to be part of a global movement toward better health for all.

Learn more about our work at https://t.co/9vMVYqyUN8

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc. All Rights Reserved.

[$ @ibuybonds]

RT @NYSE_UAMY: $UAMY This week, Managment teams from U.S. Antimony and @americas_silver convened in Potosi, Bolivia to tour the first of it…

[Westwater Resources Inc @WWR_Inc]

Strong 2025
New website launched
Clear path forward
#Westwater #Graphite

[Westwater Resources Inc @WWR_Inc]

New website launching tomorrow
1:00 PM ET

Stay tuned. 👀

#Westwater #WebsiteLaunch

[Humacyte @humacyte]

Humacyte® has received a minimum $1.475M purchase commitment for our Symvess® acellular tissue–engineered vessel-tyod to support a clinical evaluation and outreach program in the Kingdom of Saudi Arabia.
This program will help expand awareness of Symvess among healthcare providers across KSA as we continue discussions on establishing a joint venture and commercialization license in the region.

This is another important step in our global expansion efforts and we look forward to supporting medical teams as they evaluate the potential of Symvess to improve patient care.

For more details read the full press release here: 🔗 https://t.co/0gK9IFiBVP

#Humacyte #Symvess #Biotechnology #GlobalHealth #TissueEngineering #RegenerativeMedicine #MedicalInnovation #ATEV #Innovation
PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at https://t.co/Eg2XmrWjCQ

INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.

WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc. All Rights Reserved.